Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures

BACKGROUND: B-cell depleting drugs show promise for treating multiple sclerosis. OBJECTIVE: We sought predictors of optimal response to rituximab, a B-cell depleting antibody, to help guide therapy selection. METHODS: We performed a post hoc study of 30 relapsing multiple sclerosis patients with bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, Enrique, Piccio, Laura, Mikesell, Robert J, Trinkaus, Kathryn, Parks, Becky J, Naismith, Robert T, Cross, Anne H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433328/
https://www.ncbi.nlm.nih.gov/pubmed/28607711
http://dx.doi.org/10.1177/2055217315623800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433328/
https://www.ncbi.nlm.nih.gov/pubmed/28607711
http://dx.doi.org/10.1177/2055217315623800

Ejemplares similares